EVALUATION OF A BOOSTER DOSE OF A/VIETNAM/1203/04 (H5N1) VACCINE ADMINISTERED

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。流感是由几种相关病毒引起的一种常见感染。它每年在美国造成20,000-40,000人死亡。当一种新的流感病毒感染人类时，这种感染可以迅速在世界各地传播。一些新的人类流感病毒来自禽流感病毒。最近，一些禽流感病毒株感染了亚洲的人们。其中一种流感病毒被称为A/H5N1。疫苗可以预防感染和疾病。疫苗的工作原理是使身体产生一种名为抗体的蛋白质来对抗感染。有时需要一剂以上的疫苗，这样身体才能产生足够的抗体来对抗感染。已经开发出一些疫苗来预防感染流感病毒。流感疫苗可以预防流感及其引发的健康问题。这些疫苗是由部分灭活的流感病毒制成的。这些疫苗是作为对手臂的一剂强心针。您之前曾参加过一项研究，以测试一种针对A/H5N1禽流感病毒的实验性疫苗。作为这项研究的一部分，您接种了两剂A/H5N1禽流感疫苗。甲型H5N1禽流感疫苗被认为是研究性的(或试验性的)，这意味着它还没有得到美国食品和药物管理局的批准，可以在普通公众中使用。该疫苗由赛诺菲巴斯德公司(以前称为安万特巴斯德公司)生产。这项研究的目的是找出接种第三剂A/H5N1疫苗是否会提高人体的禽流感抗体(细菌战士)水平。这项研究的信息将帮助研究人员和公共卫生官员确定需要多少剂量的A/H5N1疫苗才能产生对禽流感的最佳保护水平。来自美国3个研究地点(洛杉矶生物医学研究所、罗切斯特大学和马里兰大学)的约450人参加了早些时候的一项研究，以测试A/H5N1禽流感疫苗。大约400名接种了两剂A/H5N1禽流感疫苗(不是安慰剂或灭活疫苗)且目前身体健康的人将被要求参加这项研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Influenza (the flu) is a common infection caused by several related viruses. It is responsible for 20,000-40,000 deaths each year in the United States. When a new strain of flu infects people, the infection can spread around the world quickly. Some of the new human flu viruses come from bird flu viruses. Recently, some strains of bird flu viruses have infected people in Asia. One of these flu strains is called A/H5N1. Vaccines can prevent infection and disease. Vaccines work by causing the body to make proteins called antibodies that fight infection. Sometimes more than 1 dose of vaccine is needed so that the body will make enough antibodies to fight infection. Some vaccines have been developed to prevent infection with flu viruses. Flu vaccines protect against flu and the health problems it causes. These vaccines are made from parts of killed flu virus. These vaccines are given as a "shot" in the arm. Your have previously taken part in a research study to test an experimental vaccine against the A/H5N1 bird flu virus. As part of this study, you received two doses of the A/H5N1 bird flu vaccine. The A/H5N1 bird flu vaccine is considered investigational (or experimental) which means that it has not been approved by the U.S. Food and Drug Administration for use in the general public. The vaccine is made by sanofi pasteur, inc. (previously known as Aventis Pasteur, Inc.). The purpose of this study is to find out if giving a third dose of the A/H5N1 vaccine will boost the body's level of bird flu antibodies (germ fighters). Information from this study will help researchers and public health officials to determine how many doses of A/H5N1 vaccine will be needed to produce the best level of protection against bird flu. About 450 individuals from 3 study sites in the United States (L.A. Biomedical Research Institute, University of Rochester and University of Maryland) took part in a the earlier research study to test the A/H5N1 bird flu vaccine. About 400 individuals who received two doses of the A/H5N1 bird flu vaccine (not the placebo or inactive shot) and are currently healthy will be asked to take part in this study.